<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03595254</url>
  </required_header>
  <id_info>
    <org_study_id>MSchure</org_study_id>
    <nct_id>NCT03595254</nct_id>
  </id_info>
  <brief_title>Digital Cognitive Behavior Therapy Program for Suicide Prevention</brief_title>
  <acronym>TM2</acronym>
  <official_title>Thrive-Montana: A Computerized Cognitive Behavior Therapy (cCBT) Program to Reduce Depression, Anxiety, Suicidal Ideation and Behaviors for Rural Montanans</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Montana State University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Montana Department of Public Health and Human Services</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Montana State University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the efficacy of Thrive, a computerized cognitive behavior therapy
      program, to reduce depression and anxiety symptoms and to reduce suicidal thinking among
      adults. The first 450 participants will participate in a randomized waitlist controlled
      trial. The remaining 550 participants will be provided the program immediately upon enrolling
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The efficacy of Thrive has been studied among patient and community populations and has shown
      to effectively reduce depression and anxiety symptoms among adults with moderate to severe
      depression symptoms at baseline.

      This study will examine whether Thrive can also reduce suicidal thinking for persons
      exhibiting at least moderate depression symptoms. The first phase of the study will implement
      a randomized waitlist controlled trial. The second phase of the study will examine the
      effects in a open trial. Outcome assessments will occur at baseline, 4- and 8-weeks (12- and
      16-weeks for the waitlist group) with a 6-month follow-up assessment for all participants.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date type="Anticipated">August 15, 2018</start_date>
  <completion_date type="Anticipated">June 30, 2019</completion_date>
  <primary_completion_date type="Anticipated">May 15, 2019</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>randomized waitlist controlled trial (first 450 participants) Open trial (following 550 participants)</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Concise Health Risk Tracking</measure>
    <time_frame>2 Weeks</time_frame>
    <description>Suicidal Thinking</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Generalized Anxiety Disorder Scale-7</measure>
    <time_frame>2 Weeks</time_frame>
    <description>Anxiety symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Work and Social Adjustment Scale</measure>
    <time_frame>1 Year</time_frame>
    <description>Functioning</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Connor-Davidson Resilience Scale - Abbreviated Version</measure>
    <time_frame>1 month</time_frame>
    <description>Resilience</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Health Questionnaire-9</measure>
    <time_frame>2 Weeks</time_frame>
    <description>Depression</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Suicidal Ideation</condition>
  <condition>Depression</condition>
  <condition>Anxiety</condition>
  <arm_group>
    <arm_group_label>Thrive Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Online cognitive behavior therapy program</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Waitlist Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Wait 8 weeks before receiving program access</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Thrive</intervention_name>
    <description>Computerized Cognitive Behavior Therapy program</description>
    <arm_group_label>Thrive Intervention</arm_group_label>
    <arm_group_label>Waitlist Control</arm_group_label>
    <other_name>Thrive-Montana</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Montana resident

          -  18+ years old

          -  Have regular access to broadband internet

          -  PHQ-9 score greater than 4

        Exclusion Criteria:

          -  No Montana residency

          -  &lt; 18 years old

          -  No broadband internet access

          -  PHQ-9 score less than 5
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Montana State University</name>
      <address>
        <city>Bozeman</city>
        <state>Montana</state>
        <zip>59717-2940</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Mark B Schure, PhD</last_name>
      <phone>406-994-3248</phone>
      <email>mark.schure@montana.edu</email>
    </contact>
    <contact_backup>
      <last_name>Traci Miyakawa</last_name>
      <phone>406-994-7696</phone>
      <email>tracim@montana.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>June 29, 2018</study_first_submitted>
  <study_first_submitted_qc>July 11, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 23, 2018</study_first_posted>
  <last_update_submitted>July 11, 2018</last_update_submitted>
  <last_update_submitted_qc>July 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Montana State University</investigator_affiliation>
    <investigator_full_name>Mark B. Schure, Ph.D.</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Suicidal Ideation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nicotine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

